This Phase I trial, sponsored by City of Hope Medical Center, focuses on a novel cellular immunotherapy approach for high-risk intermediate grade B-lineage non-Hodgkin lymphoma (NHL). The use of genetically modified T cells expressing a CD19-specific CAR represents a significant advancement in the treatment of recurrent or high-risk NHL, a market with substantial unmet medical needs. The competitive landscape includes established CAR T-cell therapies, but this trial's focus on central memory T cells may offer improved persistence and efficacy. Given the increasing demand for innovative therapies in oncology, successful outcomes could position the sponsor favorably for future commercialization and partnerships, particularly in the context of expanding CAR T-cell applications.